arrow
B

Betül Oran

The University of Texas MD Anderson Cancer Center
H指数:49
被引数:8,296

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy

供者特异性HLA错配:单倍型与7/8位点错配无关供者造血干细胞移植联合PTCy

2026-06-170
PRE
Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis

建立供者年龄和类型权衡模型,以在采用移植后环磷酰胺预防措施的同种异基因造血细胞移植中进行个性化选择

Leukemia
IF13.4
2026-01-120
PRE
Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center

吉达西他滨在移植后高风险急性髓系白血病和骨髓增生异常综合征患者中改善了无复发生存期:单中心II期研究结果

2026-01-010
OA
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study

异基因造血细胞移植在新时代晚期系统性肥大细胞增生症中的应用:一项CIBMTR研究

2025-09-220
PRE
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation

新诊断的FLT3酪氨酸激酶域突变急性髓系白血病患者的结局:NPM1共突变的治疗意义

Cancer
IF5.1
2025-08-090
OAAI
Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

供者年龄和供-受者性别不匹配对HLA匹配的亲属与非亲属供者造血细胞移植结局的影响

BLOOD
IF23.1
2024-11-050
PRE
Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

供者年龄较轻的半相合造血干细胞移植疗效改善

BLOOD
IF23.1
2024-11-050
PRE
Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

大剂量分次马利兰、氟达拉滨、克拉屈滨、替莫唑胺和维奈克拉(Cladillac)预处理方案用于极高危AML/MDS:一项Ⅱ期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
2024-08-142
OAAI
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation

在接受异基因干细胞移植的老年急性髓系白血病患者中,克拉屈滨/低剂量阿糖胞苷/维尼托克的低强度治疗优于强化化疗

CANCER
IF5.1
2024-05-292
PRE
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation
2024-02-291
OAAI
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study
2024-02-050
PRE
Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation
2024-02-013
PRE
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning

白消安和氟达拉滨清髓性预处理对骨髓纤维化的移植结果

2023-12-014
OAAI
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
2023-10-132
OAAI